ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 102 filers reported holding ASCENDIS PHARMA A/S in Q2 2018. The put-call ratio across all filers is 1.38 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $15,079,000 | +11.1% | 146,025 | 0.0% | 1.66% | +22.2% |
| Q2 2022 | $13,574,000 | -73.9% | 146,025 | -67.0% | 1.36% | -61.9% |
| Q1 2022 | $51,932,000 | -12.8% | 442,502 | 0.0% | 3.58% | -0.4% |
| Q4 2021 | $59,530,000 | -50.9% | 442,502 | -41.8% | 3.59% | -34.0% |
| Q3 2021 | $121,233,000 | -39.6% | 760,606 | -50.2% | 5.44% | -37.4% |
| Q2 2021 | $200,793,000 | -6.4% | 1,526,359 | -8.3% | 8.69% | +15.3% |
| Q1 2021 | $214,488,000 | -28.5% | 1,664,242 | -7.4% | 7.54% | -43.7% |
| Q4 2020 | $299,828,000 | +8.1% | 1,797,745 | 0.0% | 13.38% | -16.5% |
| Q3 2020 | $277,428,000 | +4.3% | 1,797,745 | 0.0% | 16.03% | -15.9% |
| Q2 2020 | $265,886,000 | +17.9% | 1,797,745 | -10.3% | 19.06% | -6.7% |
| Q1 2020 | $225,574,000 | -4.9% | 2,003,147 | -2.8% | 20.44% | -8.1% |
| Q2 2019 | $237,225,000 | -1.5% | 2,060,135 | +0.6% | 22.23% | -7.5% |
| Q1 2019 | $240,912,000 | +77.5% | 2,046,832 | -5.5% | 24.02% | +38.6% |
| Q4 2018 | $135,752,000 | -11.6% | 2,166,832 | 0.0% | 17.34% | +12.0% |
| Q3 2018 | $153,542,000 | +6.5% | 2,166,832 | 0.0% | 15.48% | -16.7% |
| Q2 2018 | $144,138,000 | +1.7% | 2,166,832 | 0.0% | 18.57% | -7.5% |
| Q1 2018 | $141,711,000 | +100.2% | 2,166,832 | +22.6% | 20.08% | +32.4% |
| Q4 2017 | $70,779,000 | +10.5% | 1,766,832 | 0.0% | 15.16% | +17.1% |
| Q3 2017 | $64,048,000 | +30.6% | 1,766,832 | 0.0% | 12.94% | +4.8% |
| Q2 2017 | $49,047,000 | -0.9% | 1,766,832 | 0.0% | 12.35% | -15.1% |
| Q1 2017 | $49,471,000 | +38.3% | 1,766,832 | 0.0% | 14.55% | +23.5% |
| Q4 2016 | $35,761,000 | +0.7% | 1,766,832 | 0.0% | 11.78% | +6.5% |
| Q3 2016 | $35,513,000 | +51.5% | 1,766,832 | 0.0% | 11.07% | +72.8% |
| Q2 2016 | $23,446,000 | -10.9% | 1,766,832 | +24.5% | 6.40% | -3.0% |
| Q1 2016 | $26,329,000 | – | 1,419,332 | – | 6.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |